Features

Lonza half-year business performance fully on track

In the first half of 2014, Lonza’s specialty ingredients and pharma & biotech segments both delivered a sound performance despite currency headwinds and are fully on track to deliver the growth targets. more »

Jul 24, 2014

Xention awarded £1.4m from Technology Strategy Board to develop new medicines for atrial fibrillation

The company is now well positioned to advance candidate drugs in its pipeline towards the clinic. more »

Jul 24, 2014

Biosimilar Retacrit effective in chemotherapy-induced anemia

Results show that the company's European biosimilar epoetin, Retacrit (epoetin zeta) was effective and well tolerated in the management of chemotherapy-induced anemia in patients with solid tumours, lymphoma and myeloma. more »

Jul 24, 2014

FDA approves Gilead's Zydelig for three types of blood cancers

Zydelig is being granted traditional approval to treat patients whose chronic lymphocytic leukemia (CLL) has returned (relapsed). more »

Jul 24, 2014

Integra pIpette streamlines screening of novel protein therapeutics

Integrating an Integra VIAFLO 96 multichannel pipette into their high throughput expression facility has enabled Molecular Partners to streamline the discovery and development of a novel class of targeted protein therapeutics termed DARPins. more »

Jul 24, 2014 Lab Products

BMS and Ono Pharmaceutical announce strategic immuno-oncology collaboration in Japan, South Korea and Taiwan

As part of the agreement, BMS and Ono will jointly develop and commercialise Opdivo (nivolumab) and Yervoy (ipilimumab) across a broad range of tumour types. more »

Jul 24, 2014

Medical Expo

Built with Metro Publisher™